Yuqing Dai1, Ping Liang2, Jie Yu3. 1. Department of Interventional Ultrasound, Chinese PLA Medical College & Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, China. 2. Department of Interventional Ultrasound, Chinese PLA Medical College & Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, China. liangping301@hotmail.com. 3. Department of Interventional Ultrasound, Chinese PLA Medical College & Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, China. jiemi301@163.com.
Abstract
PURPOSE OF REVIEW: Surgical treatment of breast cancer is becoming increasingly more minimally invasive. We review the development status of percutaneous management for primary breast cancer and the evidence relating to tumor size as a fundamental determinant of treatment clinical outcome. RECENT FINDINGS: It is safe and feasible for percutaneous management to treat breast cancer. For tumor size ≤ 2 cm, percutaneous management is a promising alternative modality. For tumor size ≤ 3 cm, it is controversial whether percutaneous management can achieve similar effects to surgery, especially its long-term effects. For tumor size > 3 cm, it is still in the initial exploration stage and showed the potential in the treatment of unresectable cancer by benefitting the local control of primary cancer. Percutaneous management of breast cancer is a valuable method for breast cancer treatment in selected patients. However, it will be necessary to provide the high level of evidence for widespread clinical application.
PURPOSE OF REVIEW: Surgical treatment of breast cancer is becoming increasingly more minimally invasive. We review the development status of percutaneous management for primary breast cancer and the evidence relating to tumor size as a fundamental determinant of treatment clinical outcome. RECENT FINDINGS: It is safe and feasible for percutaneous management to treat breast cancer. For tumor size ≤ 2 cm, percutaneous management is a promising alternative modality. For tumor size ≤ 3 cm, it is controversial whether percutaneous management can achieve similar effects to surgery, especially its long-term effects. For tumor size > 3 cm, it is still in the initial exploration stage and showed the potential in the treatment of unresectable cancer by benefitting the local control of primary cancer. Percutaneous management of breast cancer is a valuable method for breast cancer treatment in selected patients. However, it will be necessary to provide the high level of evidence for widespread clinical application.
Authors: Saskia Litière; Gustavo Werutsky; Ian S Fentiman; Emiel Rutgers; Marie-Rose Christiaens; Erik Van Limbergen; Margreet H A Baaijens; Jan Bogaerts; Harry Bartelink Journal: Lancet Oncol Date: 2012-02-27 Impact factor: 41.316
Authors: Shima Roknsharifi; Kapil Wattamwar; Michael D C Fishman; Robert C Ward; Kelly Ford; Salomao Faintuch; Surekha Joshi; Vandana Dialani Journal: Radiographics Date: 2021 Jul-Aug Impact factor: 5.333
Authors: Mirelle Lagendijk; Marissa C van Maaren; Sepideh Saadatmand; Luc J A Strobbe; Philip M P Poortmans; Linetta B Koppert; Madeleine M A Tilanus-Linthorst; Sabine Siesling Journal: Int J Cancer Date: 2017-09-18 Impact factor: 7.396
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702